

FORM PTO-1449 (Modified)		Attorney Docket No. 16930-001020	Serial No.: 08/801,092			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: DOUGLAS ANTELMAN et al.				
		Filing Date: 02/14/97	Group: Unknown			
Reference Designation		U.S. PATENT DOCUMENTS				
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
___ AA						
___ AB						
___ AC						
___ AD						
___ AE						
___ AF						
___ AG						
___ AH						
___ AI						
___ AJ						
___ AK						
___ AL						
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
___ AM						
___ AN						
___ AO						
___ AP						
___ AQ						
___ AR						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
AS	Shimizu, R.T. et al., "The Smooth Muscle α -Actin Gene Promoter Is Differentially Regulated in Smooth Muscle versus Non-smooth Muscle Cells," J. Biol. Chem. 270(13):7631-7643 (1995)					
AT						
EXAMINER	DATE CONSIDERED		8/4/94			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/315,116
Filing Date	5/19/99
First Named Inventor	Antelman, Douglas, et al.
Group Art Unit	1642
Examiner Name	M. Davis
Attorney Docket Number	16930-001022

RECEIVED

APR 18 2001

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
SE	1	PCT	WO 9507708 (abstract)	/	Lee et al.	03/23/95	/	/

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SE	2	FUEYO, et al., "Expression of exogenous p16/CDKN2 products growth arrest in a glioma cell line that does not express RB protein," <i>Proceedings of the American Association for Cancer Research</i> , 37:A49 (1996)	
SE	3	XU, et al., "Enhanced Tumor Suppressor Gene Therapy via replication-deficient Adenovirus Vectors Expressing an N-Terminal Truncated Retinoblastoma Protein," <i>Cancer Research</i> , 56:2245-2249 (1996)	

Examiner Signature

[Signature]

Date Considered

8/4/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
SF 1210869 v1



PTO/SB/08B (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	09/315,116		
		Filing Date	May 19, 1999		
		First Named Inventor	Antelman, Douglas		
		Art Unit	1636		
		Examiner Name	Sumesh Kaushal		
Sheet	3	of		Attorney Docket Number	016930-001022US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
								<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SK	0001	WILLS, et al., Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer, Human Gene Therapy (September 1994), pgs. 1079-1088, volume 5, Mary Ann Liebert, Inc. Publishers	
R	0002	SCHULER, et al., A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer, Human Gene Therapy (September 1998), pgs. 2075-2082, Mary Ann Liebert, Inc. Publishers	
R	0003	NIELSEN, et al., Combination Therapy with the Farnesyl Protein Transferase Inhibitor SCH66336 and SCH58500 (p53 Adenovirus) in Preclinical Cancer Models, Cancer Research (December 1, 1999), pgs 5896-5901, volume 59.	
R	0004	NIELSEN, et al., p53 Tumor Suppressor Gene Therapy for Cancer, Cancer Gene Therapy (1998), pgs. 52-63, Vol. 5, No. 1.	
R	0005	REID, et al., Intravascular Adenoviral Agents in Cancer Patients: Lessons From Clinical Trials, Cancer Gene Therapy (2002), pgs. 980-986, Nature Publishing Group.	
R	0008	WILLS, et al., Tissue-Specific Expression of an Anti-Proliferative Hybrid Transgene from the Human Smooth Muscle α -actin Promoter Suppresses Smooth Muscle Cell Proliferation and Neointima Formation, Gene Therapy (2001), pgs. 1847-1854, Nature Publishing Group.	

Examiner Signature		Date Considered	8/4/04
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.